| 1 |
26734075 | Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study. | 2016 |
1 |
| 2 |
25897968 | Effects of thiazolidinedione therapy on inflammatory markers of type 2 diabetes: a meta-analysis of randomized controlled trials. | 2015 |
1 |
| 3 |
24793974 | Hyperglycemia impairs cytotrophoblast function via stress signaling. | 2014 Nov |
1 |
| 4 |
22415569 | Effects of rosiglitazone on the cardiovascular profile in postmenopausal women without diabetes mellitus: interplay of thiazolidinediones and hormone therapy. | 2012 Jul |
1 |
| 5 |
17087601 | Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus. | 2007 |
1 |
| 6 |
17280678 | Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. | 2007 Nov |
1 |
| 7 |
17305652 | Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. | 2007 Mar |
1 |
| 8 |
17932317 | Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production. | 2007 Dec |
1 |
| 9 |
16957566 | Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. | 2006 Oct |
1 |
| 10 |
15899724 | Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. | 2005 May |
1 |
| 11 |
15990085 | Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation. | 2005 Aug 19 |
1 |
| 12 |
15045127 | Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. | 2004 Apr |
1 |
| 13 |
12615670 | Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. | 2003 Apr 1 |
4 |
| 14 |
12661797 | Rosiglitazone: potential beneficial impact on cardiovascular disease. | 2003 Mar |
1 |
| 15 |
12940867 | Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. | 2003 Sep |
12 |
| 16 |
12957323 | Insulin resistance, inflammation, and the prediabetic state. | 2003 Aug 18 |
1 |
| 17 |
12037506 | [Rosiglitazone: a clinical development focused on cardio-vascular prevention]. | 2002 Apr |
1 |
| 18 |
11887975 | Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism. | 2001 Nov |
1 |